📊 TNBI Key Takeaways
Is Tanke Biosciences Corp (TNBI) a Good Investment?
Despite 19.8% revenue growth, Tanke Biosciences remains operationally unprofitable with negative operating income (-$420.5K) and net income (-$860.2K), coupled with a severe 170.6% YoY EPS decline. Critical data staleness (September 2013, over 12 years old) severely limits assessment reliability; current fundamentals cannot be validated.
Why Buy Tanke Biosciences Corp Stock? TNBI Key Strengths
- Revenue growth of 19.8% year-over-year demonstrates top-line expansion
- Reasonable gross margin of 31.8% indicates operational viability at product level
- Conservative capital structure with low leverage (Debt/Equity 0.12x) and adequate liquidity (Current Ratio 1.61x)
TNBI Stock Risks: Tanke Biosciences Corp Investment Risks
- Company is unprofitable at both operating and net income levels, destroying shareholder value (ROE -5.5%, ROA -3.0%)
- Earnings per share collapsed 170.6% year-over-year despite revenue growth, signaling deteriorating unit economics
- Critical data freshness issue: financial data from September 2013 (12+ years old) makes any current assessment invalid; unable to assess company's present fundamental state
- Negative interest coverage (-2.0x) indicates inability to service debt from operations
- Trading on OTC markets with no recent insider activity suggests limited institutional confidence
Key Metrics to Watch
- Path to operating profitability and positive net income
- Operating cash flow and free cash flow generation
- Quarterly earnings trends and gross margin sustainability
- Cash burn rate relative to $5.1M cash balance
Tanke Biosciences Corp (TNBI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Tanke Biosciences Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
TNBI Profit Margin, ROE & Profitability Analysis
TNBI vs Market Sector: How Tanke Biosciences Corp Compares
How Tanke Biosciences Corp compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tanke Biosciences Corp Stock Overvalued? TNBI Valuation Analysis 2026
Based on fundamental analysis, Tanke Biosciences Corp has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tanke Biosciences Corp Balance Sheet: TNBI Debt, Cash & Liquidity
TNBI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tanke Biosciences Corp's revenue has grown significantly by 20% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.34 reflects profitable operations.
TNBI Revenue Growth, EPS Growth & YoY Performance
TNBI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2013 | $6.0M | -$158.8K | N/A |
| Q2 2013 | $5.6M | -$49.1K | N/A |
| Q1 2013 | $4.5M | -$545.3K | N/A |
| Q3 2012 | $6.2M | $570.1K | $0.04 |
| Q1 2012 | $4.5M | -$671.0K | $-0.05 |
| Q3 2011 | $5.7M | $760.2K | $0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tanke Biosciences Corp Dividends, Buybacks & Capital Allocation
TNBI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tanke Biosciences Corp (CIK: 0001452011)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TNBI
What is the AI rating for TNBI?
Tanke Biosciences Corp (TNBI) has an AI rating of SELL with 45% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TNBI's key strengths?
Claude: Revenue growth of 19.8% year-over-year demonstrates top-line expansion. Reasonable gross margin of 31.8% indicates operational viability at product level.
What are the risks of investing in TNBI?
Claude: Company is unprofitable at both operating and net income levels, destroying shareholder value (ROE -5.5%, ROA -3.0%). Earnings per share collapsed 170.6% year-over-year despite revenue growth, signaling deteriorating unit economics.
What is TNBI's revenue and growth?
Tanke Biosciences Corp reported revenue of $16.3M.
Does TNBI pay dividends?
Tanke Biosciences Corp does not currently pay dividends.
Where can I find TNBI SEC filings?
Official SEC filings for Tanke Biosciences Corp (CIK: 0001452011) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TNBI's EPS?
Tanke Biosciences Corp has a diluted EPS of $0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TNBI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tanke Biosciences Corp has a SELL rating with 45% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TNBI stock overvalued or undervalued?
Valuation metrics for TNBI: ROE of -5.5% (sector avg: 15%), net margin of -5.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TNBI stock in 2026?
Our dual AI analysis gives Tanke Biosciences Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TNBI's free cash flow?
Tanke Biosciences Corp's operating cash flow is N/A, with capital expenditures of $2.4M.
How does TNBI compare to other Market stocks?
Vs Default sector averages: Net margin -5.3% (avg: 12%), ROE -5.5% (avg: 15%), current ratio 1.61 (avg: 1.8).